5 Best-performing Canadian Pharma Stocks (Updated January 2026)

1. HLS Therapeutics (TSX:HLS)

Year-on-year gain: 26.6 percent
Market cap: C$149.8 million
Share price: C$4.76

HLS Therapeutics focuses on drugs for cardiovascular and central nervous system problems, often through partnerships. The company specializes in acquiring and commercializing pharmaceuticals that address unmet needs, including Vascepa to reduce cardiovascular risk and Clozaril for treatment-resistant schizophrenia.

Additionally, the company generates revenue from a diversified portfolio of royalty interests on various products marketed by third parties. HLS in-licensed the exclusive rights to the treatments Nilemdo and Nexlizet, both of which are already approved in other countries, from Esperion Therapeutics (NASDAQ:ESPR) in May.

Health Canada's November approval of LDL-cholesterol-lowering treatment Nilemdo represents the most significant catalyst for the company since the launch of Vascepa, positioning HLS as a dominant leader in the Canadian cardiovascular market. The company is targeting Nilemdo's commercial launch in Q2 2026.

Health Canada also issued a notice of non-compliance for HLS' Nexlizet cholesterol-reducing treatment. The firm said the decision was related to chemistry, manufacture and controls data, not clinical data or safety.

2. Satellos Bioscience (TSXV:MSCL)

Year-on-year gain: 14.49 percent
Market cap: C$141.04 million
Share price: C$0.79

Satellos Bioscience is a Canadian pharmaceutical company expanding treatment options for muscle disorders.

The company has focused specifically on Duchenne muscular dystrophy, developing therapies that target the specific biological pathways involved in regenerating and repairing muscle tissue. Its lead candidate, SAT-3247, targets a protein called AAK1, which regulates the activity of stem cells that activate and differentiate new muscle fibers.

In the fourth quarter of 2025, Satellos administered the first dose to a patient in its 11 month open-label follow-up study for adults who completed its initial Phase 1b trial. The study seeks to demonstrate the lasting impact of the significant functional improvements observed earlier in the year.

On December 9, the company received investigational new drug clearance from the US Food and Drug Administration (FDA) and several other global regulators to initiate BASECAMP, a global Phase 2 randomized, placebo-controlled study to evaluate SAT-3247 in pediatric patients.

3. Knight Therapeutics (TSX:GUD)

Year-on-year gain: 14.29 percent
Market cap: C$592.59 million
Share price: C$6.00

Knight Therapeutics is a specialty pharmaceutical company headquartered in Montreal, Québec.

It operates on an acquisition and in-licensing model, obtaining the rights to innovative medicines from global pharmaceutical companies and commercializing them across Canada and Latin America.

The company was originally founded by the former leaders of Paladin Labs, which was acquired by Endo International in 2014. In June 2025, Knight bought the Paladin business back from Endo for C$107 million, adding over 40 products to its Canadian roster. The additions helped drive 32 percent revenue growth year-on-year to a record C$122.55 million in Q3. The company projects its Knight Canada subsidiary will be the company's top revenue-contributor within two years.

4. BioSyent (TSXV:RX)

Year-on-year gain: 10.07 percent
Market cap: C$146.89 million
Share price: C$12.90

BioSyent is a specialty pharmaceutical company focused on in-licensing or acquiring established, high-margin healthcare products for the Canadian and international markets. Its growth is anchored by brands in iron health and women's wellness. Its flagship brand, FeraMAX, has been Canada's leading iron supplement for over a decade.

The company's 2024 acquisition of Tibella, a treatment for menopausal symptoms, has been a major growth driver. According to its third quarter earnings report. BioSyent's sales grew 19 percent year-on-year in Canada and 94 percent in the international market.

5. NurExone Biologic (TSXV:NRX)

Year-on-year gain: 6.45 percent
Market cap: C$47.54 million
Share price: C$0.66

NurExone Biologic is behind ExoTherapy, a drug-delivery platform that uses exosomes, which are nano-sized extracellular vesicles, to create treatments for central nervous system disorders, spinal cord injuries and traumatic brain injuries. It is a less invasive alternative to cell transplantation, which requires surgery and carries the risk of rejection.

NurExone’s first nano-drug, ExoPTEN, uses a proprietary sIRNA sequence delivered with the ExoTherapy platform to treat spinal cord injuries. ExoPTEN received orphan drug designation from the US FDA in October 2023. The company expects to initiate its Phase 1/2a first-in-human trial for acute spinal cord injury in H2 2026.

It continues to make significant progress, with recent preclinical studies demonstrating strong, dose-dependent vision recovery in glaucoma models and improved motor function in spinal cord injury models.

NurExone announced plans for a US exosome production facility in Indianapolis, Indiana, in September. According to a release, "The GMP compliant site would produce exosomes both for NurExone’s therapeutic pipeline and for a growing business-to-business opportunity in regenerative aesthetics."

In December, the firm began planning for small-scale production of ExoPTEN in Israel to support its clinical trial.